Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158180 | 1.00 | GLS (0.40) | GLSGLANPSR1L3MBTL1 | |
| SCHEMBL21726165 | 0.85 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL9196022 | 0.85 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL21726166 | 0.85 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL8927527 | 0.80 | L3MBTL1 (0.37) | L3MBTL1 | |
| SCHEMBL8926357 | 0.80 | L3MBTL1 (0.37) | L3MBTL1 | |
| SCHEMBL1740025 | 0.79 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL11986915 | 0.79 | GLS (0.37) | GLSGLANPSR1 | |
| SCHEMBL11986916 | 0.79 | GLS (0.40) | GLSGLANPSR1 | |
| SCHEMBL264858 | 0.78 | GLS (0.38) | GLSGLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037940-A1 | PYRAZOLE-1-CARBOXAMIDES AS RIP1 KINASE INHIBITORS | BISICHEM CO., LTD. (KR) | 2025-02-20 | — | — | WO | disclosed |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| EP-4296273-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Future Medicine Co., Ltd. (KR) | 2023-12-27 | — | — | EP | disclosed |
| CN-117279907-A | Pyrrolidone derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023011629-A1 | PYRROLIDONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2022203427-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | 퓨쳐메디신 주식회사 | 2022-09-29 | — | — | WO | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016112088-A1 | ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | CRABTREE ACQUISITION CO, LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005112914-A2 | PHENOLIC ANTIOXIDANTS FOR THE TREATMENT OF DISORDERS INCLUDING ARTHRITIS, ASTHMA AND CORONARY ARTERY DISEASE | ATHEROGENICS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6818622-B2 | ADMINISTERING OVER A PERIOD OF AT LEAST THREE MONTHS A MATRIX METALLOPROTEINASE INHIBITOR FOR TREATMENT OF A PATIENT HAVING CANCER OR INFLAMMATION | DARWIN DISCOVERY LTD. (GB) | 2004-11-16 | — | — | US | disclosed |
| EP-0981366-B1 | SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS | DARWIN DISCOVERY LTD (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-20020035065-A1 | Selective MMP inhibitors having reduced side-effects | BIRD JOHN (GB) | 2002-03-21 | — | — | US | disclosed |
| EP-0804430-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5656662-A | TREATING OR PREVENTING ATHEROSCLEROTIC DISORDERS, INHIBITING INFLAMMATORY CYTOKINES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5504107-A | ANTICOAGULANTS, PREVENTING ATHEROSCLEROSIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1995032194-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | MPO, ALOX15B, ALOX12 | GLS 1521/4885GLA 283/4885NPSR1 2078/4885 |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | ADORA2A, ADORA3, ADORA2B | GLS 2841/4885GLA 4128/4885NPSR1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.